Coronavirus vaccines are moving towards clinical trials, promises several biotech companies in the US

Edex Live | April 09, 2020

Just three months after the outbreak of the coronavirus pandemic, several biotech companies in the United States have ramped up their efforts to fight the disease with accelerated schedules for creating new vaccines and beginning clinical trials for potential treatments. In normal circumstances, vaccine development would take around 10 years. But the pharmaceutical industry is racing to compress this timeline with the support of non-profit organisations, government agencies and regulatory authorities. In just a few months, more than two dozen companies have announced promising vaccine programmes, speeding through the early stages of testing unlike ever before, The Strait Times reported.

Spotlight

The biopharmaceutical industry is at a pivotal time in medical discovery, which has enormous potential to further revolutionize the treatment of costly and debilitating diseases like Alzheimer’s, cancer, heart disease, and hepatitis C. Our ability to harness recent scientific advances
continues to accelerate, and the potential benefits to patients are becoming clearer. Much of this progress is attributed to a deeper, molecular-level understanding of all dif

Spotlight

The biopharmaceutical industry is at a pivotal time in medical discovery, which has enormous potential to further revolutionize the treatment of costly and debilitating diseases like Alzheimer’s, cancer, heart disease, and hepatitis C. Our ability to harness recent scientific advances
continues to accelerate, and the potential benefits to patients are becoming clearer. Much of this progress is attributed to a deeper, molecular-level understanding of all dif

Related News

INDUSTRIAL IMPACT

ADM Further Expands Microbial Science and Technology Innovation Capabilities with Investment in Precision Fermentation Leader Acies Bio

ADM | October 22, 2021

ADM a global leader in nutrition and agricultural origination and processing, annoThis investment will help ADM more quickly advance projects in the field of precision microbial fermentation by leveraging Acies Bio’s extensive microbial capabilities and contract manufacturing services. “Microbial technology is unlocking disruptive opportunities in sustainable agriculture, sustainable materials and fuels, and alternative proteins, We’re propelling growth opportunities by working with innovators who appreciate our unique combination of expertise, capacity and access to feedstocks. Now, by investing to become a minority owner in Acies Bio, we’re opening up the door to new collaboration with an innovative, complementary business to meet the growing demand for products developed via microbial fermentation.” Ian Pinner, ADM chief strategy and innovation officer. Founded in 2006, Acies Bio develops innovative, proprietary microbial and synthetic biology-based platforms and technologies and also offers contract R&D services in microbial strain engineering and fermentation for customers in key growth segments, including sustainable agriculture, functional foods and bio-based industrial chemicals. “Acies Bio’s core mission is to use the nearly unlimited power of microbial diversity to drive disruptive innovation and help create a more sustainable bio-based future,” said Enej Kuščer, Acies Bio's co-founder and director. “This strategic partnership with ADM will allow Acies Bio to expand and accelerate the development of our platform technologies, which aim to replace synthetic chemicals and the often carbon-intensive production currently used in food and agriculture with microbial, bio-based products.” “This investment from ADM will also allow Acies Bio to expand our infrastructure and increase the high-throughput capabilities of our SmartRoute platform, which will allow faster development of new technologies and products,” said Štefan Fujs, Acies Bio's co-founder and director. “This will speed-up the internal pipeline and also help us deliver more quality services to our partners and collaborators.” ADM’s investment in Acies Bio is being made through ADM Ventures, the company’s corporate venture capital arm. ADM Ventures invests in cutting-edge start-ups with disruptive technologies across three key areas: human nutrition, animal nutrition and sustainability. ADM Ventures also seeks startups that utilize ADM’s assets and feedstocks to produce sustainable materials, in addition to technologies that enhance the effectiveness or efficiency of ADM’s operations. About Acies Bio Acies Bio is a leading European microbial biotechnology company that develops new bioproducts and sustainable production processes for diverse industrial sectors, including pharma, food/feed, agricultural, and industrial biotechnology. With an emphasis on sustainability and using Acies Bio’s unique SmartRoute microbial platform, including synthetic biology and strain engineering, high-throughput screening, precision bioprocess and downstream development, the company has successfully developed and scaled numerous innovative products and precision fermentation technologies with industrial partners worldwide. About ADM At ADM, we unlock the power of nature to provide access to nutrition worldwide. With industry-advancing innovations, a complete portfolio of ingredients and solutions to meet any taste, and a commitment to sustainability, we give customers an edge in solving the nutritional challenges of today and tomorrow. We’re a global leader in human and animal nutrition and the world’s premier agricultural origination and processing company. Our breadth, depth, insights, facilities and logistical expertise give us unparalleled capabilities to meet needs for food, beverages, health and wellness, and more. From the seed of the idea to the outcome of the solution, we enrich the quality of life the world over.

Read More

Sartorius Stedim Biotech Closes Acquisition of Slovenian Purification Specialist BIA Separations

Sartorius | November 03, 2020

Sartorius Stedim Biotech (SSB), a leading partner of the biopharma industry, successfully closed the acquisition of the Slovenian purification specialist BIA Separations. The transaction was completed on November 2, 2020, after receiving the required approvals. "BIA's portfolio is highly complementary to Sartorius Stedim Biotech. We are thus creating an excellent offering for the manufacturing of gene therapies and other advanced therapies, and are pleased to welcome 120 new employees," said Dr. Joachim Kreuzburg, Chairman of the Board and CEO of Sartorius Stedim Biotech. The total purchase price of the transaction is 360 million euros of which 240 million euros were paid in cash and 120 million euros in SSB shares. Both parties have further agreed on three tranches of earn-out payments based on performance over the next five financial years. SSB has been preparing to integrate BIA Separations so this can now be initiated despite the special conditions prevailing during the pandemic. BIA Separations develops and manufactures market-leading products for purification and analysis of large biomolecules, such as viruses, plasmids and mRNA, which are used in cell and gene therapies and other advanced therapies. BIA's technology for manufacturing-scale purification is already used in production of the first commercialized advanced therapeutics, and the company also has a strong presence with such novel drug candidates in the clinical pipeline. Expecting continued very strong double-digit sales growth over the next few years, BIA is forecasted to earn sales revenue of approx. 25 million euros in 2020 at profit margins that will be accretive to the underlying EBITDA margin of the Sartorius Stedim Biotech Group. The transaction is not expected to have any material impact on Sartorius Stedim Biotech's 2020 results.

Read More

MEDTECH

Alloy Therapeutics Acquires deepCDR Biologics to Bring Bioinformatics and Machine Learning to its Antibody Discovery Offering

Alloy Therapeutics | December 10, 2021

Alloy Therapeutics, a biotechnology ecosystem company, announced it has acquired deepCDR Biologics, a Basel, Switzerland-based developer of deep learning technology for antibody discovery and optimization. The team and technology stack will form new bioinformatics and machine learning capabilities for Alloy and will be fully integrated into Alloy Discovery Services complementary workflow and processes. Alloy will expand the Basel deepCDR site as a permanent Alloy research facility and will hire additional computational scientists and developers as it grows with the Alloy network. The deepCDR engine combines deep sequencing and deep learning methods with a proprietary mammalian display process to select from a wide range of antibodies and rapidly identify candidates with the highest possible affinity and developability profiles. The company was a spinoff of ETH Zurich and Department of Biosystems Science and Engineering and was founded by Sai Reddy, an Associate Professor of Systems and Synthetic Immunology at ETH Zurich and an expert in immunogenomics and machine learning-guided protein engineering. “Uniting deepCDR and Alloy reflects our conviction in the power of network effects and scientific collaboration—together our companies’ capabilities are amplified to better serve the global scientific community in its pursuit of finding the best medicines for patients. Our network of partners will be able to work with deepCDR’s machine learning engine in a way that otherwise would have been cost prohibitive or inaccessible. The ongoing technology improvements will enhance the output of Alloy platforms and Alloy Discovery Services for the benefit of all of our drug discovery partners.” Alloy Therapeutics CEO and Founder Errik Anderson DeepCDR’s technology will strengthen Alloy Discovery Services capabilities with patent-pending machine learning-powered antibody repertoire screening, in silico library screening, and mammalian display. DeepCDR thoughtfully integrates wet lab antibody screening and characterization with the computational tools to enable a powerful learning loop generating real world results. The deepCDR team will form Alloy’s new Basel, Switzerland operations and comprises expertise in antibody engineering and optimization, bioinformatics, and in silico library screening. “We are thrilled to join Alloy on its mission of empowering scientific entrepreneurs and democratizing foundational drug discovery capabilities,” said deepCDR founder Sai Reddy. “The data sets and infrastructure within Alloy unlock powerful new opportunities for the deepCDR technology and team that will in turn enable us to help drug discovery teams more effectively and efficiently find the best antibody candidates. We envision a future where Alloy will be a leader in unifying real-world patient, genomic, and protein sequence data to empower integrated AI and ML drug discovery and engineering.” About Alloy Therapeutics Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners, Alloy democratizes access to tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics. The company facilitates affordable, non-exclusive access to the entire drug discovery community from academic scientists, small and medium biotech, to the largest biopharma. Alloy’s lead offering, the ATX-Gx™ platform, is a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Alloy is headquartered in Boston, MA with labs in Cambridge, UK; Basel, CH; San Francisco, CA; and Athens, GA. As a reflection of Alloy’s relentless commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation.

Read More